Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK regulator spells out the safety actions underway:

This article was originally published in Clinica

Executive Summary

A list of actions taken by the UK medical device regulator in response to adverse incident notices during 2002 has been published in the MDA's Adverse Incident Reports 2002 Device Bulletin. There are some 26 groups of responses in all, by the following technical units: biosciences and implants: imaging and acute care; primary and community care; wheeled mobility and searing centre. The reports range from a safety notice outlining best practice in the use of ceramic femoral heads, to developing guidelines on the use of monophasic and biphasic defibrillators, and to issuing safety notices on structural front leg defects of ambulance stretchers. (As of April 1, the MDA has been part of the merged Medicines and Healthcare products Regulatory Agency).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT061789

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel